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Background: Because Candida albicans is resistant to several antifungal antibiotics, there is a need to identify other
less toxic natural products, particularly antimicrobial proteins, peptides or bacteriocin like inhibitory substances. An
attempt has been made to purify and characterise an anti-Candida compound produced by Enterococcus faecalis.
Results: An anti-Candida protein (ACP) produced by E. faecalis active against 8 C. albicans strains was characterised
and partially purified. The ACP showed a broad-spectrum activity against multidrug resistant C. albicans MTCC 183,
MTCC 7315, MTCC 3958, NCIM 3557, NCIM 3471 and DI. It was completely inactivated by treatment with proteinase
K and partially by pronase E.
The ACP retained biological stability after heat-treatment at 90°C for 20 min, maintained activity over a pH range
6–10, and remained active after treatment with α-amylase, lipase, organic solvents, and detergents. The
antimicrobial activity of the E. faecalis strain was found exclusively in the extracellular filtrate produced in the late
logarithmic growth phase. The highest activity (1600 AU mL-1) against C. albicans MTCC 183 was recorded at 48 h
of incubation, and activity decreased thereafter. The peptide showed very low haemagglutination and haemolytic
activities against human red blood cells. The antimicrobial substance was purified by salt-fractionation and
chromatography.
Partially purified ACP had a molecular weight of approximately 43 KDa in Tricine-PAGE analysis. The 12 amino acid
N terminal sequence was obtained by Edman degradation. The peptide was de novo sequenced by ESI-MS, and
the deduced combined sequence when compared to other bacteriocins and antimicrobial peptide had no
significant sequence similarity.
Conclusions: The inhibitory activity of the test strain is due to the synthesis of an antimicrobial protein.
To our knowledge, this is the first report on the isolation of a promising non-haemolytic anti-Candida protein
from E. faecalis that might be used to treat candidiasis especially in immunocompromised patients.
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Antimicrobial and antimycotic peptides are small cat-
ionic and amphipathic molecules, generally with fewer
than 50 amino acids. These ubiquitous peptides have
been isolated from prokaryotes and eukaryotes in the
plant, bacterial, fungal, and animal kingdoms [1,2]. Na-
ture has strategically placed antimicrobial and antifungal
peptides as a first line of defence between the host* Correspondence: utpalroy@gmail.com
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reproduction in any medium, provided the ororganism and its surrounding environment, because
these peptides are able to inhibit quickly a wide
spectrum of infectious microbes without significant tox-
icity to the host organism. When insects are infected
within a short period they secrete an array of cationic
peptides to combat the invading organism [3]. Although
antimicrobial peptides (AMP) are the primary means of
combating organisms in lower forms of life, these pep-
tides have an adjunct role in the immune system of
phylogenetically more advanced organisms.
There is a large array of antifungal proteins with differ-
ent structures. In addition to the well-known glucanasesral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.biomedcentral.com/1471-2180/12/132[4], chitinases [5], thaumatin-like proteins [6], defensins
[7] and ribosome-inactivating proteins [8], there is a di-
versity of other antifungal proteins such as lipid transfer
proteins [9] and protease inhibitors [10].
Both fungi and humans are eukaryotes and at the mo-
lecular level, their cells are similar. This makes it more
difficult to find or design drugs that target fungi without
affecting human cells. Consequently many antifungal
drugs cause side effects. Some of these side effects can
be life threatening if the drugs are not used properly.
Despite chemical therapies, serious fungal infections re-
main difficult to treat, and resistance to the available
drugs is emerging [11]. Antifungals work by exploiting
differences between mammalian and fungal cells to kill
the fungal organism without dangerous effects on the
host. A common theme with most of these wide-
spectrum AMPs is that they lyse the cell membranes of
the pathogens without harming the host targets. Despite
this non-specific mechanism, many of these peptides do
not lyse mammalian membranes at concentrations that
can inhibit the pathogen [12].
In the last decades, the incidence of fungal infections
by pathogenic C. albicans and other related human op-
portunistic yeast species has increased dramatically due
to the rise in the number of immunocompromised
patients. Several Candida species especially C. albicans
normally inhabit the oral cavity, respiratory and intes-
tinal tracts, and vaginal cavity of humans and animals.
In recent years, there has been a marked increase in the
incidence of treatment failures in candidiasis patients re-
ceiving long-term antifungal therapy, which has posed a
serious problem in its successful use in chemotherapy.
Candida cells acquire multidrug resistance (MDR) dur-
ing the course of the treatment [13].
Many bacterial strains, and particularly their enzymes,
that perform catalysis efficiently at low temperatures are
used in a number of biotechnology applications [14].
Enterococci, as part of the natural intestinal flora of
humans and animals, are known to play an important
role in maintaining microbial balance [15,16]. Many dif-
ferent enterocins have been described from Enterococcus
faecalis and E. faecium. Some of these peptides showed
activity against Escherichia coli [17] and Salmonella
pullorum [18].
Since the literature on bacterial antifungal proteins is
rather scanty compared with that on bacterial bacterio-
cins, there is a pressing need to explore and isolate from
new sources potential bacteria capable of producing
novel AMPs and to characterise them for further appli-
cations. In the present study, we report the purification
and characterisation of an antifungal protein produced by
E. faecalis, that shows broad-spectrum activity against the
indicator organisms, multidrug resistant C. albicans with
negligible haemolytic activity.Results
Characterization of species
The promising anti-mycotic strain in the present study
was determined to be gram-positive cocci, acid produ-
cing, non-motile, catalase and oxidase negative. The
strain showed good growth at 6.5% (w/v) NaCl at 14 and
37°C. In addition it was esculin hydrolysis-positive as it
fermented mannose which is the characteristic of the
genus Enterococcus. The producer of the anti-mycotic
principle was identified as Enterococcus faecalis based on
its physiological and biochemical characteristic. Based
on the 16S rDNA gene sequence, the strain was identi-
fied as E. faecium [19]. Further, using the primers EM1A
and EM1B [20], an amplicon of approximately 685 base
pairs was observed on 1.2% (w/v) agarose gel confirming
the strain to be E. faecium. However, this strain reduced
potassium tellurite and produced black colour colonies,
indicating the species E. faecalis.
The two wild type isolates (DI and WI) of the patho-
genic indicator organism were identified as C. albicans
based on 18S ribotyping. The sequences of the DI
and WI isolates showed closest homology (99%) to
the sequences of C. albicans M60302.YSASRSUA and
AJ005123, respectively.
Determination of inhibitory spectrum
The susceptibilities of various multidrug resistant
C. albicans strains to growth inhibition by the super-
natant as well as dialysed concentrate of E. faecalis are
presented in Table 1. The supernatant and dialysed con-
centrate also showed inhibitory activity against one wild
type C. albicans strain (DI) isolated from a diabetic pa-
tient from Goa. Amongst these strains, maximum activ-
ity was observed against C. albicans strains MTCC 183,
MTCC 3958, MTCC 7315, and NCIM 3471 and mini-
mum activity was observed against wild type C. albicans
(DI) (Figure 1a, b, c) and C.krusei (data not shown). The
biological activity of ACP at different dilutions is shown
in Figure 1 (d and e) against MTCC 183.
Antimicrobial activity of cell wall and cytoplasmic
extracts
The antimicrobial activity of the cell wall and cytoplas-
mic extracts of E. faecalis was determined using a cut-
well agar assay on MGYP and BHI plates. No zone of
inhibition was produced against C. albicans MTCC 3958,
Pseudomonas aeruginosa MTCC 741 and Staphylococcus
aureus MTCC 737 by cell wall and cytoplasmic extracts,
establishing that the inhibition was mainly due to extra-
cellular substances.
Kinetics of antifungal protein production
Biomass and antimycotic protein production by E. faecalis
in modified trypticase soya (mTS) broth, was analysed at
Table 1 Inhibitory spectrum of anti-Candida protein ACP against different indicator organisms
Strain Identified organisms Indicator organisms Zone of inhibition
210 E. faecalis Yersinia intermedia (AGM 108–5) 25 mm
Candida albicans >18 mm
(NCIM 3471, MTCC183, MTCC 7315,
MTCC 227 and MTCC 3958)
Dialysed Concentrate MTCC183 and MTCC 7315 55 mm, 47 mm
Wild type C. albicans (DI) 13 mm
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reached the stationary phase after 20 h. Prolonged incuba-
tion up to 56 h promoted degradation of the ACP but no
lysis of biomass. No ACP was produced within 8 h at
14°C, but it was produced during the active growth phase,
and its concentration reached a maximum at 48 h, at the
middle of the maximum stationary phase. The highest ac-
tivity (1600 AU mL-1) against C. albicans (MTCC 183)
was recorded between 44–48 h of incubation and
decreased thereafter. The pH dropped rapidly during the
exponential phase, probably because of the strong produc-
tion of acid associated with growth.Effects of heat, pH, and Hydrolytic Enzymes
The activity of the cell-free supernatant (CFS) was stable
upon treatment at different temperatures, for up to 90°C
for 20 min, but the activity was lost completely after
boiling and autoclaving (Table 2). The antimycoticFigure 1 a. Biological activity of ACP against C. albicans (MTCC 7315)
ammonium sulfate fractionation, The zone of inhibition was detected in 85
activity was not detected in supernatant. c. Mild biological activity of ACP
Goa. d and e. Different concentration of dialyzed concentrate of ACP showproperty of the CFS also remained unaffected at the pH
range of 6.0–8.0. However, at pH values of 5.0 and 9.0
the activity was reduced by 50%, whereas at pH values of
2.0, 4.0 and 10.0 the activity was completely lost.
The ACP was sensitive to different proteolytic enzymes
(proteinase K and pronase E) confirming its protein-
aceous nature whereas it was resistant to pepsin, α-amylase,
lipase, lysozyme and trypsin at the concentration of
1.0 mg mL-1 (Table 2).Effects of surfactants, organic solvents and storage
The antimycotic peptide ACP remained fully active
when treated with different surfactants and organic sol-
vents as mentioned in ‘Methods’. The activity was
enhanced by 33.4% in the presence of SDS (1.0%w/v)
(Table 2). Long-term storage (1 year) at −80°C did not
affect the antimicrobial activity (98%), but a slight reduc-
tion (20%) in activity at 4°C and −20°C was found.. b. Biological activity of ACP against C. albicans (MTCC 183) after 85%
% palette dissolved in 20 mmol sodium phosphate buffer pH 8.0, but
against wild type C. albicans (DI) isolated from a diabetic patient in BITS
ing zone of inhibition against a lawn of C. albicans MTCC 183.
Figure 2 Kinetics of anti-mycotic protein and biomass production of E. faecalis.
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The highest antifungal activity against different C. albicans
strains was present mainly in the fraction precipitated with
85% ammonium sulfate (Figure 1b). Fractions precipitated
with 30% and 50% ammonium sulfate exhibited weak
inhibition. The supernatant obtained after 85% ammo-
nium sulfate precipitation clearly did not exhibit any
antifungal activity. The antifungal substance present in
the 85% cut-off also inhibited germ tube formation in
C albicans NCIM 3471 (data not shown). As is clear
from Table 3, ammonium sulfate precipitation resulted
in an approximate 2-fold increase in specific activity.Table 2 Effect of enzymes, heat, pH, organic solvents and sur
biological activity retained, -ve sign, loss of biological activity
Treatment (w/v) Activity
Trypsin (1.0 mg ml-1) +
Pronase E (1.0 mg ml-1) -
Proteinase K (1.0 mg ml-1) –
Pepsin (1.0 mg ml-1) +
α-Amylase (1.0 mg ml-1) +
Lipase (1.0 mg ml-1) +
Lysozyme (2.0 mg ml-1) +
37°C, 60°C for 90 min +
90°C for 20 min +
100°C for 30 min -
100°C for 90 min -
121°C for 15 min -
Control at 4°C +
(pH) 6.0, 7.0 and 8.0 +
(pH) 2.0, 4.0 and 10.0 -After ion- exchange chromatography using DEAE
Sepharose, the adjacent fractions 31–35 in the
chromatogram, showed biological activity (Figure 3),
and the specific activity increased 17-fold. After gel fil-
tration, the recovery was approximately 22-fold. Based
on the purification steps summarised in Table 3, it was
concluded that the total active antimycotic protein
recovered was 0.45% only.
Direct detection of activity on PAGE
After gel filtration, partially purified active pooled frac-
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DTT (0.1 mol) +













Culture Supernatant 400 1600 0.4025 39751 1 100
Ammonium sulfate and dialysis 10 3200 0.0444 72072 1.8 11
Ion Exchange Chromatography 6 1600 0.0023 695652 17.5 0.57
Gel Filtration 2 1600 0.0018 888888 22.4 0.45
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hibition on the C. albicans MTCC 3958 overlaid gel was
shown in a Petri dish (Figure 4), wherein a simultan-
eously silver stained gel showed a corresponding band
that was responsible for the biological activity. Based on
the polypeptide molecular weight marker, the molecular
mass of the active peptide was estimated to be approxi-
mately 43 kDa (Figure 4). We did not observe any bio-
logical activity of the bands using glycine Native PAGE.Amino acid sequencing
The first 12 amino acid residues of the N-terminal were
determined by Edman degradation. The minor sequence
obtained from the twice repeated N-terminal sequencing
was GPGGPG, and the same partial sequence was
matched for homology. Complete homology was not
found in the NCBI BLAST result. However, the GPGG
sequence matched a known ABC transporter, i.e. ABC
Transporter peptide permease and hypothetical protein.
The first three amino acid residue GPG matched with
N-terminal sequence of enterocin 1071B [21,22]. Like-
wise the GPG sequence was also observed in EntC2 [23].
Analysis of the major N-terminal sequence DEVYTVKSFigure 3 Chromatogram of antimycotic protein ACP produced by E. f
280 nm. Fractions (31–35) showing biological activity.(S+S’)GLS revealed the presence of S’ suggesting a modi-
fied serine which is a feature of class I lantibiotics. This
sequence was almost similar to those found in autolysin
and hypothetical protein of E. faecalis.Amino acid composition and sequence analysis done by
de novo sequencing
Based on the de novo sequence the combined peptides
having 40 amino acid residues were assembled. Individ-
ual peptides having m/z 718, 1039 and 601 were found.
The combined peptide did not contain any charged
acidic residues (Asp, Glu). Hydrophobic amino acids
constituted (42.5%, excluding Gly). The peptides did not
significantly match any known proteins present in the
MASCOT and BLASTp databases. The amino acid se-
quence of ACP (40 residues) obtained from peptide frag-
ments after digestion of the antimycotic protein with
trypsin was analyzed by MS/MS spectra using PEAKS
Studio Version 4.5 SP2 [Bioinformatics Solutions] with
subsequent de-novo sequencing. The peaks obtained
are indicated in the sequence below, and overlapping
residues are shown in bold. The de novo spectra for pep-
tides are given in Figure 5a, b, and c.aecalis on DEAE Sepharose, absorbance of fractions taken at
Figure 4 Tricine-PAGE of ACP purification fractions and gel overlay with C. albicans (MTCC 183). Lane 1, molecular weight marker. Lane 2,
dialyzed concentrate after 85% ammonium sulfate fractionation. Lane 3, pooled active fractions collected through DEAE Sepharose matrix. Lane 4,
silver stained fractions after gel filtration using Sephadex-G 75. Lane 5, Inhibition zone by antimycotic protein (ACP) on the overlay gel.
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did not identify any sequence with homology in the Pro-
tein Data Bank (PDB). Only a small patch of sequence
matched; for example, a WL motif that was found 2 times
in enterocin 1071B amino acid sequence [23], and was
found 4 times in WLPPAGLLGRCGRWFRPWLLWLQS
GAQYKWLGNLFGLPGK in the combined de novo se-
quence (Figure 5d) of ACP. Earlier study on Ponericin W1
and W2 revealed WL and GL motifs and the presence of
hydrophobic residues.
MIC of the dialysed concentrate containing ACP
The highest minimal inhibitory concentration (MIC),
1067 μg mL-1 of dialysed concentrate containing ACP was
found against wild type C. albicans (DI) whereas the low-
est MIC, 133 μg mL-1 was found against MTCC 183 and
MTCC 7315.The MIC of ACP against MTCC 3958 was
267 μg mL-1 (Figure 6).
Haemolytic and haemagglutination activity assays
Freshly grown E. faecalis, streaked on sheep blood agar
plates, did not produce a clear haemolytic zone whereas
a clear transparent zone was produced by Streptococcus
pyogenes and S. aureus used as controls. The cytotoxic
effect of the extracellular proteins of E. faecalis against
human RBCs was determined by haemolytic and haem-
agglutination assays. The effect of various concentrations
of the purified anti-Candida compound on human ery-
throcytes is reported in Figure 7. The ACP showed neg-
ligible haemolytic activity up to the concentration of
0.4 mg mL-1 whereas a very weak haemolytic activity
of 3.76% at the concentration of 6.4 mg mL-1 of anti-
Candida protein was found.No haemagglutination activity of ACP was found up
to1.6 mg mL-1; however, a slight haemagglutination activ-
ity was observed at 3.2 mgmL-1 concentration (Figure 8).
Discussion
Biochemical characteristics and fatty acid methyl ester
(FAME) analysis identified the strain as E. feacalis,
whereas 16 S rDNA sequencing identified the strain as E.
faecium [19]. Potassium tellurite reduction, however, dis-
tinguished the strain as E. faecalis rather than E. faecium.
The concentrate made from the CFS of the test strain
inhibited 7 multidrug resistant strains of C. albicans.
There are several bacteriocins from E. faecalis and other
species origin [15,24], but antimycotic peptides or proteins
are rare. Pseudomonas syringie and some Bacillus species
produce antifungal peptides, but no such reports about E.
faecalis [25] were found. The genus Enterococcus belongs
to a group of important lactic acid bacteria (LAB) that
participate and contribute towards different fermentation
processes. Their functionality in dairy and meat products
has been reported in detail [26,27]. Several bacteriocins
produced by Enterococcus species [24] or other entero-
cocci of different origins [15], have been reported and
characterized at the biochemical and genetic levels. Several
antifungal peptides (iturins, bacillomycins) were discov-
ered from Bacillus and Pseudomonas. Nikkomycins, pro-
duced by Streptomyces tendae and S. ansochromogenes,
and polyoxins, produced by S. cacaoi, are the most widely
studied antifungal peptides, whereas antifungal peptides
from Enterococcus species [25,28] are rare. Various strains
of Bacillus subtilis produce iturin A and bacillomycin L
peptide. Iturins inhibited the growth of fungi including
Aspergillus niger, C. albicans, and F. oxysporum [29,30].
a. De novo spectra for peptide 718.29 m/z, WLPPAGLLGRCGR 
b. De novo spectra for peptide 1,039.72 m/z, WFRPWLLWLQSGAQYK 
c.
d.
De novo spectra for peptide 601.24 m/z, WLGNLFGLPGK 
Figure 5 a. De novo spectra for peptide 718.29 m/z, WLPPAGLLGRCGR. b. De novo spectra for peptide 1,039.72 m/z, WFRPWLLWLQSGAQYK.
c. De novo spectra for peptide 601.24 m/z, WLGNLFGLPGK. d. Combined de novo sequence of ACP having 3 peptide residues of m/z ratio 718,
1039 and 601.
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Figure 6 Antimycotic effect of ACP on the growth of C. albicans (MTCC 183, 3958, 7315, and DI), analyzed by a microbroth dilution
assay. Well (a) medium only, well (b) ACP in the medium only, well (c) Grown C. albicans in the medium. Rows A–D, normal growth of Candida
albicans, wells treated with different concentrations of ACP.
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that iturin A was effective against dermatomycoses and
had a wide spectrum of antifungal properties and low al-
lergenic effects [31]. Unfortunately, bacillomycin L and
iturin A are haemolytic, which may reduce their potential
use as antifungal drugs [32].
In an era of increased incidence of fungal infections
in immunocompromised patients [33,34] and greater
resistance to ‘frontline’ antifungal therapies [35], there is a
growing need to discover new antifungal therapies. Al-
though newer azole derivatives such as voriconazole are
more effective and have cidal activity against filamentous
fungi such Aspergillus fumigatus [36], these derivatives are
fungistatic and not fungicidal against pathogenic yeasts. The
inability to kill yeasts leads to resistance to azole in pro-
longed infections and increases the likelihood that these
agents will lack efficacy in severe Candida infections in im-
munosuppressed patients. Amphotericin B has also been
commonly used to treat serious fungal infections, but in
contrast to azoles, amphotericin B is fungicidal against
yeasts. Nevertheless, resistance to amphotericin B is
slowly developing in selected Candida species [37] and
there are significant side effects associated with its use,
including nephrotoxicity. Although recently developed
antifungal agents, including the peptide-based agents’Figure 7 Haemolytic activity of the dialyzed concentrate containing Amicafungin and caspofungin, are very promising, resist-
ance to these therapies has already been reported [38-40]
and will no doubt become more widespread. The devel-
opment of resistance to current antifungal agents, the
limited efficacy, and the side effects associated with sev-
eral of these agents increase the importance of continued
development of new alternative approaches.
The identified Enterococcus faecalis strain produces
the antimycotic substance, ACP, extracellularly. The ac-
tivity of the ACP was stable upon treatment at different
temperatures, for up to 90°C for 20 min but the activity
was lost after boiling and autoclaving. While similar
results have been reported for bacillomycin D from B.
subtilis [41] and durancin L28-1A from E. durans [42],
bacteriocin ST15 from E. faecium was inactivated when
subjected to 121°C for 20 min [43]. The antimycotic
property of the ACP also remained unaffected in the pH
range of 6.0–8.0. At pH values of 5.0 and 9.0, however, the
activity was reduced by 50% whereas at values of pH 2.0,
4.0, and 10.0 activity was lost completely. These results are
similar to those reported for the bacteriocin produced by
E. mundtii [44]. Several bacteriocins produced by entero-
cocci are known to exhibit a wide range of pH stability [45].
The ACP was stable in different organic solvents and sur-
factants; such stability has been a common feature of manyCP against human erythrocyte cells.
Figure 8 Haemagglutination activity of ACP with different
concentration.
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Bacillus species, and other LAB [43,46,47].
The ACP was fully sensitive to proteinase K and partially
sensitive to pronase E, confirming its proteinaceous nature.
Its resistance to pepsin, lysozyme and trypsin indicated that
the anti-Candida active principle may be a cyclic peptide
containing unusual amino acids and therefore more resist-
ant to protease hydrolysis [48]. These results suggested that
this antimycotic peptide could survive in the intestinal en-
vironment and might therefore be administered with food
[49]. On the other hand, the ineffectiveness of α-amylase
and lipase on antimycotic activity suggested that the ACP
might not be glycosylated and might not contain a lipid
moiety. When the ACP was heated with 1 mmol and
2 mmol β-mercaptoethaol at 80°C for 10 min to ensure
thiol residues existed in the reduced state, no particular
change in antimycotic activity was observed. This indicates
that the oxidation state of the cysteine residues may not be
important for the antimycotic activity [50]. When the dia-
lysed ACP was treated with the reducing agent DTT, no de-
crease in inhibitory activity was observed, indicating that
disulphide bonds are not responsible for biological activity.
It was also observed that storage of ACP at −80°C for 1 year
did not significantly affect biological activity. Ammonium
sulfate salt as well as sodium phosphate buffer did not in-
hibit ACP activity at the concentration used and did not
modify the result of the assay. The dialysed concentrate of
ACP, dissolved in 20 mmol sodium phosphate buffer,
weakly bound with the DEAE Sepharose matrix, indicating
that the ACP bears negative charges. Being weakly negative,
it was separated easily in native polyacrylamide gel electro-
phoresis. After purification by ammonium sulfate fraction-
ation, dialysis, anion exchange chromatography and gel
filtration, the final amount of recovered protein (0.45%) was
found very low. This could be increased by using protein
engineering and optimization methods.
Comparing the partial amino acid sequence of the puri-
fied antimycotic protein to other antimicrobial peptides and
bacteriocins by using protein-protein BLAST in NCBIrevealed no complete homology with other known bacter-
iocins or AMPs. The combined N-terminal and de novo
sequence GPGGPG. . .WLPPAGLLGRCGRWFRPWLLW
LQSGAQYKWLGNLFGLGPK had high amounts of gly-
cine, proline, leucine and tryptophan. This has been
observed in many antimicrobial peptides including bac-
teriocins like enterocin and acidocin.
It was reported earlier that the glycine-rich antifungal
peptide tenacin-3 enters the C. albicans cytoplasm [51],
although tenacin-3 seems not to induce membrane per-
meabilisation. Linear peptides with an extended structure
were characterised by an unusual proportion of one or
more amino acids (most often proline, tryptophan, or gly-
cine) [52,53]. Penaedins characterised from shrimps and
prawns had a high content of Pro/Arg/Gly residues in the
extended N-terminal domain [54]. Oxypinin 2 has a GVG
motif, and ponericin G has glycine residues flanking the
central proline, resulting in a GPG motif with calculated
grand average of hydropathicity (GRAVY) of −0.683.20.
The presence of Gly-Pro hinges in antimicrobial peptides
like oxypinins, ponericins, and cecropins supports the
antimicrobial potential of ACP, wherein a similar sequence
was observed. The regional flexibility provided by proline
was sometimes enhanced by the presence of glycine resi-
dues [55]. In another recent report, a penaedin
homologue, hyastatin from spider crab [56], was shown to
possess a Pro/Gly domain similar to the N-terminal do-
main of penaedins that bind chitin tightly. This informa-
tion strengthens the idea that the N-terminal minor
sequence GPGGPG of the anti-Candida protein in the
present study could interact with the cell wall of Candida
as a primer for antimicrobial action [56]. In such a
proline-rich sequence, a proline kink has all the potential
to create pores [57]. It was cogently argued that in cationic
hydrophobic peptides the presence of polar residues con-
fers a hydrophilic property to the proline-rich peptides. In
an earlier study conducted on curvaticin FS47, the neutral
(Gly [24%]) and hydrophobic (Ala, Ile, Leu, Val, Pro, and
Phe [47%]) residues at the N-terminal constitute a signifi-
cant proportion which helps to explain the hydrophobic
interactions that curvaticin FS47 displays. It was reasoned
that the high proportion of Gly residues (23.9% in ACP)
would likely provide a significant amount of flexibility to
the antimicrobial molecule [58]. In fact, the increase of
hydrophobicity of the peptides also correlated with fungi-
cidal activity [59]. In accordance with many other bacter-
iocins of LAB e.g., lactococcin A [60], lactacin F [61], and
curvaticin FS47 [58], a high proportion of glycine was
likely to provide a significant amount of flexibility to the
molecule. A recent study on lactococcin G, enterocin
1071B, and EntC2 suggested that the N-terminal sequence
of the peptide of each bacteriocin (LcnGβ, Ent1071B and
EntC2) is important for determining target cell specificity
[23,62].
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bial dermaseptin B was reported to be highly hydropho-
bic which could enable its binding to zwitterionic outer
and negatively charged surfaces [63]. In addition, the
part of the N-terminal sequence which contains Gly-Pro
residues and the combined de novo sequence detected
in the anti-Candida protein ACP 43 under current in-
vestigation, were supported by the inference that
proline-rich peptides (often associated with arginine)
enter cells without membrane lysis and after entering
the cytoplasm bind to and inhibit the activity of specific
molecular targets causing cell death [64]. Other studies
with model amphipathic all L- amino acid peptides with
the sequence KX3KWX2KX2K, where X=Gly, Ala, Val,
or Leu showed that the leucine-rich peptide, rather than
the Ile- or Val-containing peptide, was particularly anti-
microbial [63]. Our result is in agreement with this ob-
servation: leucine amounted to 19.6%, and proline
(13.0%) was in association with arginine.
The combined sequence derived from the de novo se-
quencing, WLPPAGLLGRCGRWFRPWLLWLQ SGAQY
KWLGNLFGLGPK, showed high content of glycine
(17.5%), proline, leucine and tryptophan. The amino acid
content also revealed that the peptide was quite hydro-
phobic due to the presence of high amounts of leucine
(22.5%), and this is believed to play a role in the interac-
tions with the cell membrane [61]. The hydrophobicities
(GRAVY) of individual peptides having m/z 718, 1039
and 601 were 0.108, -0.388 and 0.282 respectively, which
indicates that these peptides are relatively hydrophobic
and characteristic of many bacteriocins isolated from En-
terococcus species [65]. High levels of glycine (31%) and
glutamine (18%) residues in another cationic antifungal
peptide constitutively produced by S. peregrine larva
were also reported to bind C. albicans through electro-
static interaction and disturb the osmotic integrity of
treated cells [56]. In contrast, a novel glycine/leucine-
rich antimicrobial peptide, leptoglycine (glycine 59.1%
and leucine 36.4%) derived from Leptodactylus penta-
dactylus failed to inhibit C. albicans. We have used the
combined de novo sequence to predict the structure
using the PSIPRED (Protein Structure Prediction) server.
The sequence WFRPWLLWLQSGAQYK showed alpha
helical structure, which is characteristic of many anti-
microbial peptides [63].
The MIC of the ACP against wild-type C. albicans DI
was 1067 μg ml-1, whereas the lowest MIC, 133 μg mL-1,
recorded was against MTCC 183 and MTCC 7315.The
MIC of the ACP against MTCC 3958 was 267 μg mL-1
which was slightly higher than the MICs of iturin and
bafilomycin F [25]. In this study, the results of toxicity
experiments were of great interest. ACP was non-toxic
to human erythrocytes up to a tested concentration of
6.4 mg mL-1. At this concentration, the percenthaemolytic activity was 3.76 which is comparatively
much less than the haemolytic activities of baciamin
[66] and bafilomycin F [25].
It was also concluded that ACP was not able to hemag-
glutinate human red blood cells up to the concentration
of 1.6 mg ml-1 (Figure 8), however the concentration
higher than this were able to hemagglutinate the human
RBC, whereas this concentration is much more than the
MIC of the ACP. These properties taken together might
render this antimycotic protein ACP, a potent candidate
for treating candidiasis, and its related pharmaceutical ap-
plication can be established in synergy with other relevant
antifungal antibiotics of low dosage.Conclusions
In this study an antimycotic protein, ACP from the bacter-
ial strain E. faecalis was purified to near homogeneity.
This antimycotic peptide has negligible haemagglutination
and haemolytic activity and hence potentially warrants use
in synergy with low dosages of available antifungal drugs
to inhibit multidrug resistant C. albicans.Methods
Bacterial strains, growth conditions, and media
E. faecium (accession number HM481246) was routinely
propagated in TGYE medium (tryptone, 5.0 gL-1; glu-
cose, 1.0 gL-1; yeast extract, 3.0 gL-1; pH 7.2-7.4). For
ACP production, the strain was grown in optimized
mTSB medium (glucose, 2.5 gL-1; yeast extract, 2.5 gL-1;
pancreatic digest of casein, 17.0 gL-1; papaic digest of
soyabean meal, 3.0 gL-1; sodium chloride, 5.0 gL-1;
K2HPO4, 2.5 gL
-1; and pH 7.2). The indicator organism
C. albicans used in biological activity (cut-well agar)
assay was propagated in MGYP (malt extract, 3.0 gL-1;
glucose, 10 gL-1; yeast extract, 3 gL-1; peptone, 5.0 gL-1,
pH 6.4-6.8). The strain was grown in a BOD incubator
maintained at 14°C. All microbiological media compo-
nents were purchased from Hi-Media, Mumbai, India.
Different strains of C. albicans were purchased from
the Institute of Microbial Type Culture Collection
(IMTECH), Chandigarh and National Collection of In-
dustrial Microorganism (NCIM), Pune India. These yeast
strains were subcultured regularly in MGYP agar and
broth. In the current investigation, the wild-type clinical
isolates DI and WI were also used. For their species
identification, the fungal genomic DNA was extracted
using the kit RTK13. For sequencing the amplicon, ABI
3130 genetic analyser (Chromous Biotech Pvt. Ltd.
India) was used.
The test strain was subjected to carbohydrate
fermentation using the Hi-Carbo kit KB009-20KT. All
strains were stored in appropriate media with 20%
glycerol at −80°C.
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The anti-Candida activity was assayed against yeast
C. albicans MTCC 183, MTCC 3958, MTCC 7315 and
NCIM 3471 using the agar-well diffusion assay method as
described previously [19]. To determine the titre of the
antifungal activity, serial 2-fold dilutions of the extracts
were performed. The anti-Candida activity was expressed
as units AU mL-1 corresponding to the reciprocal of the
highest dilution causing inhibition of the yeast growth.Kinetics determination of E. faecalis
The kinetics of antimycotic protein production was
determined by inoculating with 1% (109 CFU mL-1) of
an overnight culture of E. faecalis in mTSB enriched
broth and incubating at 14°C under uncontrolled pH
conditions without agitation. At 4 hours interval, sam-
ples were collected to determine the optical density at
600 nm as well as pH. The antimicrobial activity was
determined assaying serial two fold dilutions of cell free
culture supernatants against C. albicans MTCC 183
(108 CFU mL-1). The antimicrobial titer was defined in
arbitrary units (AU mL-1) as the reciprocal of the highest
dilution showing inhibition around the well (5.0 mm).Preparation of cell wall and cytoplasmic extract
Sphaeroplast preparation
E. faecalis (4.0%v/v) of was grown in 10 ml mTSB broth at
14°C until the OD at 600 nm was 0.5. The cells were har-
vested by centrifugation at 10,000 rpm for 10 min at 4°C.
The pellet was resuspended at 1/10th the original volume in
STE buffer (6.7%w/v sucrose, 50 mmol Tris–HCl 1 mmol
EDTA [pH 8.0]) containing 1 mg mL-1 lysozyme [67].
The mixture was incubated at 37°C for 30 min and
was centrifuged at 5, 00 rpm for 20 min. The super-
natant was collected and stored at −80°C until use; the
pellet (sphaeroplast) was used to prepare the cytoplas-
mic extract. The antimicrobial activity of the supernatant
was tested against C. albicans MTCC 3958, C. albicans
MTCC 183, P. aeruginosa MTCC 741 and Staphylococ-
cus aureus MTCC 737.Extraction of cytoplasmic protein
The sphaeroplast obtained was resuspended in hypo-
tonic buffer (50 mmol Tris–HCl, pH-7, 1 mmol MgCl2,
25 U RNase A, 50 U DNase 1, [GeneI, India]) [68]. The
mixture was incubated on ice for 30 min. Then it was
centrifuged at 12,000 rpm for 30 min at 4°C. The super-
natant was collected and stored at −80°C until use. The
Antimicrobial activity of the supernatant was tested
against C. albicans MTCC 3958, P. aeruginosa MTCC
741, S. aureus MTCC 737.Physicochemical properties of the anti-Candida
compound
Sensitivity to heat, pH, and hydrolyzing enzymes
Temperature stability was evaluated by incubating the
CFS at various temperatures: 60°C for 90 min, 90°C for
20 min, 100°C for 20 and 30 min or autoclaved. Residual
anti-Candida activity was determined by a well-diffusion
assay against C. albicans. The effect of pH was determined
using a pH range from 2 to 10 adjusted with diluted HCl
or NaOH. After incubation at 37°C for 1 h, the resulting
CFS was subjected to an agar-well diffusion assay to rec-
ord the loss or retention of biological activity. Resistance
to several proteolytic enzymes was tested by incubating
the dialysed concentrate with pepsin, α-amylase, pronase
E, trypsin, lipase and proteinase K at a final concentration
of 1.0 mg mL-1. Buffers were used as controls. Samples
were incubated at 37°C for 90 min. The residual activity
was determined by cut-well agar assay.
Effect of organic solvents, surfactants, and storage
The sensitivity of dialyzed concentrate of ACP was
tested in the presence of several organic solvents
(methanol, ethanol, isopropanol, hexane, formaldehyde,
chloroform, acetone and acetonitrile) at a final concen-
tration of 25% (v/v). After incubation for 2 h at 37°C,
the organic solvent was evaporated using a speed vac
system (Martin Christ), and the residual antimicrobial
activity was determined. An untreated dialysed concen-
trate sample was taken as control. The effect of various
surfactants, including Triton X-100, Tween-20, SDS,
urea, EDTA, PMSF, and DTT (1.0% each) on the dia-
lyzed concentrate was also tested. To assess whether the
antifungal activity was due to the oxidation state of cyst-
eine residues, β-mercaptoethanol (1 and 2 mmol) was
used. The heat-treatment at 80°C was given for 10 min.
In order to determine the stability, the CFS, dialyzed
concentrate and partially purified ACP samples were
stored for 1 year at low temperatures (4, −20 and −80°C)
and the antimicrobial activity was compared to the freshly
purified preparation.
Partial purification of the anti-Candida compounds
E. faecalis was cultured in mTSB medium at 14°C for
48 h. Cells were harvested by centrifugation at
12,000 rpm for 30 min at 4°C, and the CFS was filtered
through 0.45 μm membranes. The culture supernatant
was subjected to sequential ammonium sulphate precipi-
tation to achieve 30%, 50% and 85% saturation at 4°C
with constant and gentle stirring for 1 h. The precipi-
tated proteins were pelleted by centrifugation at
12,000 rpm for 30 min. The protein pellet was dissolved
in sterile 20 mmol sodium phosphate buffer pH 8.0, and
dialysed using a 10 kDa MWCO membrane (Slide-A-
Lyzer Dialysis Cassette, Thermo Scientific) overnight at
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then stored at −80°C for further analysis. The 10 mL
DEAE Sepharose column (12 cm length and 1.5 cm
diameter) was packed. The packed column was equili-
brated with 20 mmol sodium phosphate buffer, and
5 mL of dialyzed concentrate was loaded on top of the
column. A linear gradient of 0 to 0.25 M NaCl, including
20 mmol sodium phosphate buffer, pH 8, was applied.
As many as 60 fractions of 3 mL were collected, and all
the fractions were tested for anti-Candida activity using
the agar-well diffusion assay. The absorbances of all frac-
tions were recorded at 280 nm. All the fractions with
antifungal activity were pooled and subjected to ultra fil-
tration (Pall Science) for concentration and removal of
salts. Gel filtration chromatography of the pooled active
sample was also performed with a Sephadex G 75 col-
umn (1.0/45 cm) for final polishing of active protein.
The column was eluted isocratically with 20 mmol so-
dium phosphate buffer, pH 8.0, at a flow rate of
40 mL h-1. All the peaks were collected as separate frac-
tions, concentrated by ultra filtration, and tested for
antifungal activity using the cut well agar diffusion assay.
The absorbance was monitored at 280 nm.Direct detection of antifungal activity on gel
Tricine Native-PAGE (10%) [69], followed by a gel over-
lay was performed with active pooled fractions from gel
filtration. After electrophoresis for 2 h at 20 mA, when
the dyefront reached at the bottom, 2 duplicate gels
were cut. One of the gels was silver stained (based on
the Alphalyze protocol). The other gel was fixed in 20%
(v/v) isopropanol and 10% (v/v) acetic acid for 30 min,
with 500 mL of MilliQ water for 1 h, and placed aseptic-
ally on an MGYP plate. To identify the active peptide
band, the tricine gel containing pooled active fraction
was overlaid by freshly grown C. albicans MTCC 3958.
After the agar solidified, the plate was incubated at 37°C
for 48–72 h until C. albicans grew uniformly over the
plate or an inhibition zone was observed.Determination of minimal inhibitory concentration (MIC)
The MIC of the dialyzed concentrate against C. albicans
(MTCC 183, MTCC 3958, MTCC 7315, and wild type
C. albicans DI from Goa) was determined by the micro-
broth dilution assay in a 96-well microtitre plate
(Tarsons). C. albicans (106 CFU mL-1) was tested for
sensitivity to 2-fold increasing dilutions of the com-
pounds (2.165 to 0.00099 mg mL-1). After incubation at
37°C for 36 h, turbidity was determined to monitor cell
growth [70]. The MIC was defined as the lowest con-
centration of the compounds inhibiting the yeast
growth.Haemolytic assay
It was essential first to study the degree of haemolysis
produced by the test strain on 5.0% (w/v) sheep red
blood cells on blood agar plates. The haemolytic activity
of the antifungal dialyzed concentrate on human ery-
throcytes was determined [71]. Human erythrocytes in
2% (v/v) suspension were exposed to various concen-
trations of ACP ranging from 6.4 to .00156 mg ml-1 at
37°C for 1 h. The cells were peletted at 1,000 rpm for
10 min and the supernatant was collected to determine
the absorbance at 450 nm using a UV Visible Spectro-
photometer (Shimadzu). In negative control sets,
erythrocyte suspension and PBS buffer was used whereas
in positive controls, lysis buffer was used for completely
lysing the erythrocytes. The percentage haemolysis was
calculated and plotted against the concentration of ACP
to determine the dose cytotoxic to human erythrocytes.
The percentage of intact erythrocytes was calculated
using the following formula.
Percent of intact erythrocytes
¼ 1 Absorbance of protein Absorbance of PBS
Absorbance of lysisbuffer  Absorbance of PBS
 
 100
Percent of hemolysis ¼ 100 percent of intact erythrocytesð Þ
Haemagglutination activity assay
In view of the findings that dialyzed concentrate exhibits
haemagglutination activity [72], a serial 2-fold dilution of
a solution of ACP (6.4 to 0.0001 mg ml-1) was added in
microtitre plates, wherein 100 μl was mixed with 100 μl
of a 2.0% suspension of human red blood cells in PBS
(pH 7.2) at 20°C. The results were observed after about
1 h when the blank without dialyzed concentrate was
fully sedimented to inspect whether the red blood cells
had agglutinated in response to the antifungal protein.
Amino acid sequencing
The corresponding protein band that showed the zone
of inhibition against Candida albicans was electro blot-
ted to a 0.45 μm Immobilon-P transfer membrane
(Millipore). After blotting at 100 mA for overnight, the
membrane was removed carefully from the cassette,
washed three times with MilliQ water to remove glycine,
and then stained for 30 sec with a freshly prepared solu-
tion of 0.1% Coomasie brilliant blue R-250 in 40%
methanol and 1.0% acetic acid. The blot was then
destained in 50% methanol until bands were visible and
background clear. The PVDF membrane was then dried
sandwiched between clean tissue papers. The stained
band of interest was tightly cut out and washed six times
in MillQ water and subjected to Edman degradation.
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sequencer, Model 494 Procise (Applied Biosystems,
USA) with 140 C analyzer at Protein Sequencing Facility,
IOWA State University, USA. The primary amino acid
sequence obtained was entered into BLAST to search
for peptides with similar sequences.
Mass spectrometry
The purified antimicrobial peptide was analyzed by matrix-
assisted laser desorption and ionization–time of flight mass
spectrometry by using a 4000 Q TRAP Mass Spectrometer
(Proteomics International, Nedlands Australia) equipped
with an ion source with visualization optics and an N2 laser
(337 nm). Protein samples were trypsin digested and pep-
tides extracted according to standard techniques [73]. All
digestion reactions were done in 50 mmol NH4HCO3 (pH
8.5) at room temperature and with an enzyme-to-peptide
ratio of 1:40 (wt/wt). Peptides were analyzed by electro-
spray ionisation mass spectrometry using the Ultimate
3000 nano HPLC system [Dionex] coupled to a 4000 Q
TRAP mass spectrometer (Applied Biosystems) with a ca-
pillary cap voltage of 1,750 V. Tryptic peptides were loaded
onto a C18 PepMap100, 3 μm [LC Packings] and separated
with a linear gradient of water/acetonitrile/0.1% formic
acid (v/v). MS/MS spectra were analyzed using PEAKS
Studio Version 4.5 SP2 [Bioinformatics Solutions]. The
mass data collected during LC/MS/MS analysis were pro-
cessed, converted into mgf files, and compared against the
Ludwig NR database by using a local MASCOT server.
The three most abundant peptides, preferably doubly
charged ions, corresponding to each MS spectrum were
selected for further isolation and fragmentation. The
MS/MS scanning was performed in the ultrascan reso-
lution mode at a rate of change in the m/z of 26.000 s-1.
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